Vaccitech PLC
F:2AB
Vaccitech PLC
Research & Development
Vaccitech PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vaccitech PLC
F:2AB
|
Research & Development
-$42.2m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Research & Development
-$150.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-104%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Research & Development
-$119m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Research & Development
-£15.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
6%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Research & Development
£9.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Niox Group PLC
LSE:NIOX
|
Research & Development
-£2.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
45%
|
CAGR 10-Years
24%
|
|
Vaccitech PLC
Glance View
Vaccitech Plc operates as a holding company. The company is headquartered in Oxford, Oxfordshire and currently employs 72 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The firm uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The firm has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).
See Also
What is Vaccitech PLC's Research & Development?
Research & Development
-42.2m
USD
Based on the financial report for Dec 31, 2024, Vaccitech PLC's Research & Development amounts to -42.2m USD.
What is Vaccitech PLC's Research & Development growth rate?
Research & Development CAGR 5Y
-7%
Over the last year, the Research & Development growth was 6%. The average annual Research & Development growth rates for Vaccitech PLC have been -28% over the past three years , -7% over the past five years .
